Xellia Pharmaceuticals ('Xellia') is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to Drug Products (FDPs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1,800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark, and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East, and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience.
Something looks off?On-site & Remote